← back to search

Harrison W. Farber

Tufts University · US
🔎 Find collaborators in Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Pulmonary Hypertension Research and Treatments, Systemic Sclerosis and Related Diseases, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, and Heart Failure Treatment and Management.
h-index
59
citations
19,280
works
469
NIH funding
primary concept
email

Recent publications

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)
Drugs - Real World Outcomes 2026cited by 1position: middledoi
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery
The Journal of Heart and Lung Transplantation 2022cited by 53position: middledoi
Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH
Genome Medicine 2021cited by 84position: middledoi
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
American Journal of Respiratory and Critical Care Medicine 2021cited by 52position: middledoi
A critical analysis of 57 cases of Hughes-Stovin syndrome (HSS). A report by the HSS International Study Group (HSSISG)
International Journal of Cardiology 2021cited by 38position: middledoi
Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide—a report by the HSS International Study Group
Clinical Rheumatology 2021cited by 27position: middledoi
Treatment of pulmonary hypertension in patients with Hereditary Hemorrhagic Telangiectasia – A case series and systematic review
Pulmonary Pharmacology & Therapeutics 2021cited by 15position: middledoi
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2020cited by 308position: lastdoi
United States Pulmonary Hypertension Scientific Registry
CHEST Journal 2020cited by 63position: middledoi
Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-analysis
Lung 2020cited by 35position: lastdoi
Predicting Survival in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2019cited by 624position: middledoi
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
European Respiratory Journal 2019cited by 114position: middledoi
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial
European Respiratory Journal 2019cited by 46position: middledoi
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
Pulmonary Circulation 2019cited by 10position: middledoi
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2018cited by 58position: middledoi
REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
The Journal of Heart and Lung Transplantation 2018cited by 46position: middledoi
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study
The Journal of Heart and Lung Transplantation 2018cited by 33position: middledoi
A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
Genome Medicine 2017cited by 108position: middledoi
Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis
The Journal of Heart and Lung Transplantation 2017cited by 48position: lastdoi
Practical considerations for therapies targeting the prostacyclin pathway
European Respiratory Review 2016cited by 49position: firstdoi
Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study
The Journal of Heart and Lung Transplantation 2016cited by 11position: lastdoi
Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
CHEST Journal 2015cited by 517position: firstdoi
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
American Journal of Hematology 2015cited by 122position: middledoi
Validation of two predictive models for survival in pulmonary arterial hypertension
European Respiratory Journal 2015cited by 100position: middledoi
Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
CHEST Journal 2014cited by 146position: middledoi
Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
The Journal of Heart and Lung Transplantation 2014cited by 135position: firstdoi
Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
CHEST Journal 2014cited by 47position: lastdoi
Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2013cited by 165position: middledoi
Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience
The Journal of Heart and Lung Transplantation 2013cited by 125position: middledoi
Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry
The Journal of Heart and Lung Transplantation 2013cited by 93position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Raymond L. Benza · Sentara Norfolk General Hospital12 papers (2014–2020)Adaani Frost · Houston Methodist11 papers (2012–2019) · 10 papers (2012–2019)Dave P. Miller · Stanford Health Care8 papers (2012–2015)C. Gregory Elliott · Intermountain Healthcare7 papers (2012–2020)David B. Badesch · German Center for Lung Research5 papers (2014–2019) · 4 papers (2012–2019)Robert P. Frantz · University of Florida4 papers (2014–2019)Robyn J. Barst · Columbia University4 papers (2012–2015)Mona Selej · KU Leuven4 papers (2017–2020)Vallerie V. McLaughlin · Medscape3 papers (2014–2019) · 3 papers (2017–2020)Wade W. Benton · Tufts University3 papers (2014–2015)Erwan Muros‐Le Rouzic · Monash University2 papers (2015–2015) · 2 papers (2014–2017)Kevin C. Wilson · Boston University2 papers (2020–2021) · 2 papers (2018–2019)Romy Christmann · AbbVie (United States)2 papers (2013–2017)Marc Humbert · Médecins Sans Frontières2 papers (2015–2019)Tammara Wood · Dartmouth College2 papers (2013–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine →